	Srodki Pieniężne I Ekwiwalent		Data
Agenus	USD 3.46M	6.08M	2025-09
Amgen	USD 9.13B	316M	2025-12
Anika Therapeutics	USD 57.99M	4.82M	2025-09
Arrowhead Research	USD 201.64M	112.94M	2025-12
AstraZeneca	USD 8.14B	1.08B	2025-09
BioMarin Pharmaceutical	USD 1.25B	36.29M	2025-09
Bristol-Myers Squibb	USD 10.21B	5.52B	2025-12
Celldex Therapeutics	USD 36.04M	12.99M	2025-09
Daiichi Sankyo	JPY 542.16B	97.68B	2025-09
Eli Lilly	USD 9.79B	6.42B	2025-09
Halozyme Therapeutics	USD 419.66M	357.8M	2025-09
Heron Therapeutics	USD 43.07M	26.55M	2025-09
Intrexon	USD 9.34M	1.77M	2024-06
Ionis Pharmaceuticals	USD 2.24B	1.94B	2025-09
Karyopharm Therapeutics	USD 37.67M	1.05M	2025-09
Ligand Pharmaceuticals	USD 664.52M	596.85M	2025-09
MacroGenics	USD 80.13M	50.56M	2025-09
Neurocrine Biosciences	USD 340.2M	76.2M	2025-09
Pfizer	USD 1.34B	295M	2025-09
Regeneron Pharmaceuticals	USD 18.87B	16.36B	2025-12
Rigel Pharmaceuticals	USD 48.53M	4.87M	2025-09
Sangamo BioSciences	USD 38.34M	13.16M	2025-06
Ultragenyx Pharmaceutical	USD 202.51M	36.4M	2025-09
Veracyte	USD 315.57M	96.07M	2025-09

Rigel Pharmaceuticals Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Feb 2026.